Ｐａｇｅ 823416 ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 通常モードに戻る ┃ ＩＮＤＥＸ ┃ ≪前へ │ 次へ≫ ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ ▼the deceased consul eldentallonia 13/9/25(水) 16:07 ─────────────────────────────────────── ■題名 ： the deceased consul ■名前 ： eldentallonia <cromnerbomsdz@allairmaxsaleoutlet.us> ■日付 ： 13/9/25(水) 16:07 ■Ｗｅｂ ： http://www.coach-outlets-discount.com/ -------------------------------------------------------------------------
| Buried inside the [url=http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/]オロビアンコ バッグ セール[/url] Dealing that progressively Hollywood sensations are wearing boots from UGG Australia [url=http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/]オロビアンコ ボディバッグ ネイビー[/url] Dealing that progressively Hollywood sensations are wearing boots from UGG Australia [url=http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/]オロビアンコ 時計 メンズ[/url] Dealing that progressively Hollywood sensations are wearing boots from UGG Australia [url=http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/]オロビアンコ 時計 評判[/url] Generic Drugs Battlefield Generic pharmaceuticals as an sector has particularly favorable demand dynamics. A variety of secular trends are converging which will advantage [url=http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/]オロビアンコ ボディバッグ レディース[/url] this market. are aggressively searching for out methods to cut down skyrocketing wellness care charges. Since [url=http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/]オロビアンコ アウトレット[/url] 1960, healthcare spending has expanded from 5% of GDP to more than 17% in 2009. Prescription drugs account for about 10% of all healthcare spending, so this is an obvious area to target. Generic versions of branded drugs normally sell for half to onethird of your price. Offered this, overall health care payers have commonly [url=http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/]オロビアンコ ベルト メンズ[/url] limited reimbursement to generic versions of specific treatments, raising the demand for them. From 2004 to 2009, generics industry share rose from 56% of prescription dollars to practically http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/ 75%. On the list of 2010 healthcare bill's primary ambitions was to improve access towards the roughly 15% of Americans with no wellness insurance coverage. By eliminating insurance coverage denials on account of existing circumstances, preventing the dropping coverage for sick individuals, and providing incentives to little firms giving coverage, a lot more people will likely be insured and much more persons will likely be http://xn--cckp2a2a8irdud5bc.lwvlosangeles.com/ capable to purchase prescriptions. Ultimately, there is certainly [url=http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/]オロビアンコ アウトレット 店舗[/url] demographics. The number of Americans more than 65 will enhance 3% a year more than the next 10 http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/ years, an added 14 million consumers getting into Medicare. Naturally, older people typically call for way more health-related care, like prescription drugs. Place it all collectively plus the image is bright for generics. This trend is set to accelerate more than the next handful of years. 6 [url=http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/]オロビアンコ ベルト クロコ[/url] in the best 20 greatest [url=http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/]オロビアンコ バッグ メンズ トート[/url] promoting branded drugs are set to drop patent protection in 2011 and 2012, with two extra [url=http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/]オロビアンコ バッグ メンズ マルイ[/url] drugs that have more than a billion dollars a year in sales expiring in 2012. That is an astounding $43 billion dollars in branded drug sales that will be open to generic competitors. So it would appear to become a slam dunk to propose generics maker Par Pharmaceuticals (PRX) as an desirable Magic Formula stock. Par generates 90% of its sales from generics, and all of its income. Par includes a two pronged strategy. Very first, it targets smaller and less competitive drugs to create. By performing this, the company can beat its competitors in filing abbreviated new drug applications (ANDAs) with the FDA, which offers 180 days of advertising and marketing exclusivity soon after the branded drug goes off patent. This can be big in the generics business windfalls from highmargin sales in these 180 days can regularly produce various "normal years" worth of profits. This offers Par a slight competitive benefit as well as enables them to charge a bit far more. Around the downside, it normally requires Par to pay royalties for the branded maker. Par just isn't pretty the slam dunk it would look [url=http://xn--cckp2a1j7eob5289c317a.tooth-body.com/]オロビアンコ バッグ オレンジ[/url] to be. The provider is just not targeting any of your aforementioned blockbuster drugs there is just an excessive amount of competition http://xn--cckp2a1j7eob5289c317a.tooth-body.com/ for them. And that is definitely one of several major problems with this industry. Scale is hugely vital http://xn--cckp2a1j7eob5289c317a.lwvlosangeles.com/ to generating economical gross margins and sustaining the legal talent required to succeed in patent challenges. At just $1 billion in sales, Par pales in comparison to Teva (TEVA) ($16 billion), Sandoz (NVS) ($9 billion), or Mylan (MYL) ($5.4 billion), not to mention a variety of related sized competitors. After exclusivity periods end, competition frequently floods in to the marketplace, driving down sales and margins. A very good example [url=http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/]オロビアンコ バッグ ブルーグレー[/url] of that is Par's largest solution: a generic version of AstraZeneca's (AZN) Toprol XL (metroprolol). Early on, competition was limited, after which there was no competition in first two quarters of 2009, driving a 100% sales improve [url=http://xn--cckp2a1j7eob5289c317a.tooth-body.com/]オロビアンコ バッグ オレンジ[/url] over 2008. Nevertheless, Watson (WPI) came in to the marketplace in late 2009, and since [url=http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/]オロビアンコ 時計 ベルト 交換[/url] then an Indian generics firm has also entered. Pricing and volumes suffered. Within the justreported 1st quarter of 2011, metroprolol sales fell 65% more than the prior year! Competitors may also result in cheating. In Q1, Par recorded a $190 million charge to settle claims in the corporation [url=http://xn--cckp2a1j7eob1457jm0f.tooth-body.com/]オロビアンコ バッグ メンズ 新作[/url] overinflating the wholesale prices [url=http://xn--cckp2a1j7eob5289c317a.tooth-body.com/]シップス オロビアンコ レディース[/url] they report to insurers. The alleged scheme is the fact that Par (and competitors) charge less to pharmacies and report higher selling prices to insurers. Given that the insurer is reimbursing the pharmacy at a greater rate than they spend for the drugs, it really is a nice reason [url=http://xn--cckp2a1j7eob0556cok1a.tooth-body.com/]オロビアンコ ボディバッグ ネイビー[/url] for the pharmacy to pick out Par's solution over a competitor's. This can be a problematic firm to worth. It really is difficult to predict the effect of new competition on current sales, and if Par shall be in a position to win exclusivity. The firm reports 12 firsttofile ANDAs, 2 possible firsttomarket possibilities, and strategy 5 to 7 new ANDA filings a year more than the following couple of years. Revenues and profitability are extremely boomandbust. Par also includes a branded drug unit referred to as Strativa, but so far this unit has been unprofitable, and quite possibly will remain so for a few years. You will find a range of possibilities for Par, but a median case puts a fair worth http://xn--cckp2a1j7eob1457jm0f.lwvlosangeles.com/ of about $40 around the stock. Due to the fact this can be a rather uncertain calculation, MagicDiligence has a neutral opinion. You can find much better Magic Formula stocks to consider. |